Related Experiment Video
Updated: Jun 27, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized
Ruth Tsang1, Lindsey Colley, Larry D Lynd
1Vancouver General Hospital, Vancouver, British Columbia, Canada.
Journal of Clinical Epidemiology
|November 18, 2008
Summary
Many randomized controlled trials (RCTs) lack the statistical power to detect significant differences in serious adverse events between drug therapies. Low power in these studies may lead to incorrect clinical conclusions and potential patient harm.
Area of Science:
- Clinical Trials
- Pharmacovigilance
- Biostatistics
Background:
- Serious adverse events (SAEs) are critical in drug safety evaluation.
- Randomized controlled trials (RCTs) are a primary source for assessing drug safety.
- Statistical analysis of SAEs in RCTs is common but often lacks power assessment.
Purpose of the Study:
- To evaluate the statistical power of RCTs to detect clinically significant differences in SAEs.
- To assess the implications of low statistical power on clinical inference in drug safety.
Main Methods:
- Systematic review of RCTs with positive efficacy and at least a twofold difference in SAEs.
- Calculation of statistical power for detecting reported SAE differences in included trials.
Main Results:
- Six RCTs were included; all analyzed SAEs without reporting statistical power.
- Calculated statistical power for detecting reported SAE differences ranged from 0.07 to 0.37 in trials with non-significant findings.
Conclusions:
- Statistical testing for SAE differences is prevalent in RCTs.
- Non-significant SAE differences in RCTs are often associated with inadequate statistical power.
- Low statistical power increases the risk of Type II errors, potentially leading to harmful clinical misinterpretations.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:37Statistical Significance
Once data is collected from both the experimental and the control groups, a statistical analysis is conducted to find out if there are meaningful differences between the two groups. A statistical analysis determines how likely any difference found is due to chance (and thus not meaningful). In psychology, group differences are considered meaningful, or significant, if the odds that these differences occurred by chance alone are 5 percent or less. Stated another way, if we repeated this...